322 related articles for article (PubMed ID: 28397632)
1. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis.
Vermeulen J; van Rooijen G; Doedens P; Numminen E; van Tricht M; de Haan L
Psychol Med; 2017 Oct; 47(13):2217-2228. PubMed ID: 28397632
[TBL] [Abstract][Full Text] [Related]
2. Influence of antipsychotics on mortality in schizophrenia: systematic review.
Weinmann S; Read J; Aderhold V
Schizophr Res; 2009 Aug; 113(1):1-11. PubMed ID: 19524406
[TBL] [Abstract][Full Text] [Related]
3. Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years.
Vermeulen JM; van Rooijen G; van de Kerkhof MPJ; Sutterland AL; Correll CU; de Haan L
Schizophr Bull; 2019 Mar; 45(2):315-329. PubMed ID: 29697804
[TBL] [Abstract][Full Text] [Related]
4. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
5. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis.
Jia N; Li Z; Li X; Jin M; Liu Y; Cui X; Hu G; Liu Y; He Y; Yu Q
Braz J Psychiatry; 2022 Nov; 44(6):664-673. PubMed ID: 36709510
[TBL] [Abstract][Full Text] [Related]
7. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
Tiihonen J; Lönnqvist J; Wahlbeck K; Klaukka T; Niskanen L; Tanskanen A; Haukka J
Lancet; 2009 Aug; 374(9690):620-7. PubMed ID: 19595447
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic treatment and mortality in schizophrenia.
Torniainen M; Mittendorfer-Rutz E; Tanskanen A; Björkenstam C; Suvisaari J; Alexanderson K; Tiihonen J
Schizophr Bull; 2015 May; 41(3):656-63. PubMed ID: 25422511
[TBL] [Abstract][Full Text] [Related]
9. Long-term antipsychotic use and brain changes in schizophrenia - a systematic review and meta-analysis.
Huhtaniska S; Jääskeläinen E; Hirvonen N; Remes J; Murray GK; Veijola J; Isohanni M; Miettunen J
Hum Psychopharmacol; 2017 Mar; 32(2):. PubMed ID: 28370309
[TBL] [Abstract][Full Text] [Related]
10. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
11. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
12. Mortality Risk Associated With Long-acting Injectable Antipsychotics: A Systematic Review and Meta-analyses of Randomized Controlled Trials.
Kishi T; Matsunaga S; Iwata N
Schizophr Bull; 2016 Nov; 42(6):1438-1445. PubMed ID: 27086079
[TBL] [Abstract][Full Text] [Related]
13. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J
CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744
[TBL] [Abstract][Full Text] [Related]
14. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis.
Pagsberg AK; Tarp S; Glintborg D; Stenstrøm AD; Fink-Jensen A; Correll CU; Christensen R
J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):191-202. PubMed ID: 28219485
[TBL] [Abstract][Full Text] [Related]
15. Mortality risk from long-term treatment with antipsychotic polypharmacy vs monotherapy among adults with serious mental illness: A systematic review and meta-analysis of observational studies.
Buhagiar K; Templeton G; Blyth H; Dey M; Giacco D
Schizophr Res; 2020 Sep; 223():18-28. PubMed ID: 32948381
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.
Baandrup L; Gasse C; Jensen VD; Glenthoj BY; Nordentoft M; Lublin H; Fink-Jensen A; Lindhardt A; Mortensen PB
J Clin Psychiatry; 2010 Feb; 71(2):103-8. PubMed ID: 19895781
[TBL] [Abstract][Full Text] [Related]
17. Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study.
Tiihonen J; Mittendorfer-Rutz E; Torniainen M; Alexanderson K; Tanskanen A
Am J Psychiatry; 2016 Jun; 173(6):600-6. PubMed ID: 26651392
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis of the use of first and second generation antipsychotics among patients suffering schizophrenia: A nationwide population-based cohort study.
Chen VC; Liao YT; Lai TJ; Lane HY; Shao WC; Dewey M; Lee CT; Lu ML
Schizophr Res; 2015 Dec; 169(1-3):406-411. PubMed ID: 26481616
[TBL] [Abstract][Full Text] [Related]
19. All-cause mortality and medication risk factors in schizophrenia: a prospective cohort study.
Tenback D; Pijl B; Smeets H; Os Jv; Harten Pv
J Clin Psychopharmacol; 2012 Feb; 32(1):31-5. PubMed ID: 22198442
[TBL] [Abstract][Full Text] [Related]
20. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis.
Smith M; Hopkins D; Peveler RC; Holt RI; Woodward M; Ismail K
Br J Psychiatry; 2008 Jun; 192(6):406-11. PubMed ID: 18515889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
